The purpose of this study was to analyse the scientific evidence concerning the effects of two enzymes -paraoxonase 1 and myeloperoxidase -on the functions of HDL-cholesterol. It is well documented that disturbed circulating lipoproteins (a high total and high LDL-cholesterol, and low HDL-cholesterol) bring about atherosclerosis and an increased risk of cardiovascular disease (CVD) which is recognised as the main cause of death all around the world. In consequence, numerous studies have focused on procedures which will improve the plasma lipoproteins profile by decreasing the total cholesterol and the LDL-cholesterol (LDL-C) and increasing the HDL-cholesterol (HDL-C). However, the anti-atherogenic role of HDL-C has been challenged in studies showing that genetically elevated HDL-cholesterol does not offer protection against CVD. Moreover, it has been found that raising the circulating HDL-cholesterol fails to reduce atherosclerosis. The doubts concerning the protective role of HDL-C have been supported by in vitro studies which indicate that the HDL-C from patients with atherosclerosis does not have a protective action, but does stimulate inflammation and free radical synthesis. The above data suggests that HDL-C, commonly recognised as protective against atherosclerosis, in some circumstances becomes pro-atherogenic, and is thus dysfunctional. Our review focuses on two enzymes -paraoxonase 1 (PON1) and myeloperoxidase (MPO) -which markedly affect the properties of HDL-C and contribute to its anti -or pro-atherogenic activity. Moreover, the effects of the diet and physical activity on PON1 and MPO are summarised with respect to the HDL-C functionality.
Introduction
It is well documented that disturbed circulating lipoproteins (a high total and high LDL-cholesterol with low HDL-cholesterol) bring about atherosclerosis and an increased risk of cardiovascular disease (CVD), which is recognised as the main cause of death all around the world [16, 19, 61] . In consequence, numerous studies have focused on medical procedures which will improve the plasma lipoproteins profile by decreasing the total cholesterol and the LDL-cholesterol (LDL-C) and increasing the HDL-cholesterol (HDL-C), thus reducing the development of atherosclerosis [49] .
The protective role of HDL-C against atherosclerosis is mostly due to its contribution to the reverse cholesterol transport (RCT) from the peripheral tissues to the liver and intestines [86] . However, it is also well documented that HDL-C has many other metabolic functions such as the prevention of free radical formation, inflammation and thrombosis, as well as contributing to the transport of a small molecules such as hormones and/or vitamins [87] .
On the other hand, it should be stressed that many studies have demonstrated that even a substantial reduction in the circulating total and LDL-cholesterol is not sufficient to reduce the atherosclerosis risk, which is consistently and inversely related to the amount of circulating HDL-cholesterol [10, 58] .
Dysfunctional HDL-cholesterol
Recently, the anti-atherogenic role of HDL-C has been challenged by studies showing that genetically elevated HDL-cholesterol does not offer protection against CVD [35, 89] . Moreover, clinical trials aimed at raising the circulating HDL-cholesterol have failed to reduce the cardiovascular outcomes [30] . The doubts concerning the protective role of HDL-C have been supported by in vitro studies which indicate that the HDL-C from patients with CVD does not have a protective action, but does stimulate inflammation and free radical synthesis [60, 77] . This data suggests that HDL-C, commonly recognised as protective against atherosclerosis, in some circumstances becomes pro-atherogenic and dysfunctional [79] . Thus, it is clear that the mechanism of the HDL-cholesterol activity against atherosclerosis is far from being fully elucidated at present, probably due to the marked variability in its structure that is followed by changes in the HDL-C functions [74] .
HDL-cholesterol structure
Circulating HDL-C consists of a very heterogeneous family, whose members differ with respect to their size, protein and lipid composition, and their surface charge [26] . At present, it is accepted that the lipidome of HDL-C is composed of 9 different phospholipids and 4 different sphingolipids, but also steroids, cholesterol esters and triglycerides [40] . Among the sphingolipids, a special role in the anti-atherogenic action of HDL-C is played by sphingosine-1-phosphate, which is recognised as a critical regulator of many physiological and pathological processes [45] . In addition, great progress in laboratory methods has enabled studies to be conducted concerning the HDL-C proteome, which have revealed many details concerning the associations between the proteins and the HDL-C functionality [14] . Fifty six proteins, including ten apolipoproteins, are associated with the HDL-C particles [71] . Moreover, many proteins in HDL-C are glycoproteins and/or glycolipids [31] . Thus, the structural variability of HDL-C makes it very sensitive to different metabolic signals which modify its structure and affect its functionality. In consequence, many authors have suggested that there is a great need for identifying the protein biomarkers for disturbances in the circulating HDL-C [25, 41, 95] . Recently, it has been proposed that among the proteins two enzymes -paraoxonase 1 (PON1) and myeloperoxidase (MPO) -may substantially affect and modify the HDL-C functionality.
Paraoxonase 1, myeloperoxidase and HDL-C
In humans, the paraoxonase (PON) family has three members named PON1, PON2 and PON3, which are encoded by three separate genes on the same chromosome 7 [67, 68] . Paraoxonase 1 (PON1, E.C. 3.1.8.1) is a calcium-dependent glycoprotein with a molecular weight of 43-45 kDa, and is composed of 355 amino acids that exhibit a wide range of important activities including the detoxification of organophosphates, nerve agents and drugs [3, 78] . At present it is well documented that native PON1 performs the lactonase activity and that the enzyme is present in almost all human organs (the liver, heart, lungs, kidneys and small intestine), but it is produced mainly in the liver and secreted into the blood [36, 48] . Early studies have indicated that both human and animal PON1 is closely associated with the HDL-C fraction, and this interaction is stabilised by the apolipoprotein A-I [9, 39, 47] . PON1 is essential for the antioxidative HDL-C protection of LDL-C [92] . On the other hand, in vitro studies have demonstrated that oxLDL-C, as well as other oxidised lipoproteins, markedly decrease the PON1 activity, thus bringing about HDL-C dysfunctionality [8] .
The idea that PON1 activity is essential for HDL-C functionality has been supported by clinical studies. Shekhanawar et al. [76] demonstrated that the PON1 activity was markedly lower in patients with coronary artery disease (CAD) vs. a healthy control group. Additionally, an increased cardiovascular risk has been found in subjects with lower PON1 activity [80] . On the other hand, it has been suggested that high levels of circulating PON1 improves the prognosis in patients undergoing a coronary artery bypass [94] . Interestingly, in subjects with familial hypercholesterolemia, statin therapy improved their lipoprotein profile but also significantly elevated their PON1 activity [82] .
A limited number of studies have been devoted to understanding the metabolic roles of PON2 and PON3. However, at present it seems that both play an important role in the body's protection against atherosclerosis and systemic inflammation, but also against cancer [22, 84, 92] .
Myeloperoxidase (MPO, E.C. 1.11.1.7) is a heme protein that is abundantly expressed in neutrophiles and to lesser extent in monocytes, which plays an important role in the body's innate immunity [42] . Mature MPO is a 150-kDa tetramer composed of two heavy subunits (59-64 kDa) and two light subunits (14 kDa) that are linked together by a disulphide bond [5, 59] . Active MPO together with hydrogen peroxide and chloride produces hypochlorous acid which has potent microbicidal actions but also pro-oxidant properties [85] . Additionally, with the neutrophil activation, MPO is released and extracellular MPO has been found in a wide range of acute and chronic inflammatory conditions [62] . The contribution of MPO to atherosclerosis has been noted in MPO-deficient hyperholesterolemic mice [13] . Moreover, the role of MPO in atherosclerosis is possibly due to nitric oxide (NO) oxidation and its adverse action on the endothelial function [1, 28, 66] .
A recent study has demonstrated that in humans MPO, PON1 and HDL-C form a functional complex in which PON1 partially inhibits the MPO activity, while MPO also partially inactivates the PON1 [31] . Moreover, it has been found that in CVD patients with normal cholesterol levels the interconnection of HDL-C with PON1 is shifted to an interconnection of HDL-C with MPO, a phenomenon that was not observed in the healthy control group [90] . Furthermore, patients with acute coronary symptoms are characterised by a higher MPO/PON1 ratio vs. the healthy control patients, and this ratio is inversely correlated with the HDL-C particle size [27, 69] . The MPO has the potential to oxidise apoA-I, which is the main apoprotein of HDL-C that is responsible for RCT and in this way generate dysfunctional HDL-C [34, 75] . Clinical data has indicated that in asymptomatic subjects, the circulating MPO together with the coronary artery calcification (CAC) can predict future atherosclerosis [17, 93] . Moreover, MPO interacts with and modifies apo B-100, which is unique to LDL-C, and the modified apoB-100 has been found in patients with atherosclerosis [21] .
Thus, it could be postulated that MPO is a potent modulator of the properties of HDL-C; however, the mutual relationship between MPO and PON1 and their effect on the HDL-C functionality is far from being fully elucidated.
Effect of diet on paraoxonase 1 and myeloperoxidase activities
There is a wealth of studies which indicate that dietary habits can markedly and positively affect the levels of circulating lipoproteins, and dietary modifications are recommended to decrease the risk of atherosclerosis and CVD [23, 55] . Similarly, data concerning a significant role of both PON1 and MPO in HDL-C functionality have led to studies concerning the effects of different dietary compounds on the enzyme activity.
Animal studies have indicated that PON1 activity is reduced in rabbits after they have been fed a high-cholesterol diet [46] . Similarly, it has been suggested that after feeding mice a pro-atherogenic diet, the circulating PON1 activity was significantly reduced [29] . In healthy men and women the plasma PON1 activity markedly decreases in response to a pro-atherogenic diet that is rich in trans fatty acids [20] . Thus, it is clear that a pro-atherogenic diet deteriorates the HDL-C functionality. On the contrary, in a cohort-based analysis of 1548 humans, Kim et al. [38] confirmed that dietary saturated myristic acid and monounsaturated gadoleic acid can positively affect the circulating PON1 activity. It has been also indicated that other dietary compounds such as extra-virgin olive oil, virgin coconut oil, vitamin C, iron and folic acid and dietary cholesterol are positive predictors of the circulating PON1 activity and the possible HDL-C functionality [6, 37, 44] . Moreover, a significant elevation in the plasma PON1 activity and the HDL-C level has been observed in hypercholesterolemic subjects, in response to anthocyanins at a dose of 160 mg two times daily [97] . It could not be excluded that substances with antioxidant potential -vitamin C and anthocyanins, but also polyphenols and vitamin E -prevent PON1 oxidation and in this way support the HDL-C functionality [18] .
Significantly fewer studies have focused on the effects of diet on MPO activity and the lipoprotein profile and/or the HDL-C functionality. Roberts et al. [73] demonstrated that a high-fibre, low fat diet decreased the circulating MPO activity and the atherosclerosis risk in healthy adolescents. Additionally, the regular consumption of buckwheat cookies rich in rutin brought about lower activity of the circulating MPO in middle-aged females [91] . Similarly, a hypocaloric diet rich in cocoa extract markedly decreased the circulating MPO activity, but also the oxidised LDL-C level in humans [33] .
On the other hand, at present there is no data about the effects of the diet on both the PON1 and MPO activity and on the HDL-C functionality. However, it should be stressed that all dietary components with antioxidant and anti-inflammatory properties have positive health effects and decrease the risk of lipoprotein disturbances, including the atheroprotective HDL functions [4, 50] .
Paraoxonase 1, myeloperoxidase and physical activity
There is no doubt that regular physical activity has to be prescribed for the prevention of many chronic diseases, including atherosclerosis [51, 65] . On the other hand, review papers analysing the associations between the circulating HDL-C and physical activity provide contradictory data that variously suggest a significant and/or a minor response of lipoproteins to physical stress [2, 12, 88] . However, taking into account the data cited above concerning the HDL-C functionality (quality), it seems feasible that physical activity has the potential to decrease atherosclerosis risks without changing the HDL-C plasma levels, i.e. without changes in its "quantity".
Until now, the data concerning the effect of physical activity on the PON1 activity has been limited and equivocal. It has been demonstrated that the plasma PON1 activity is elevated in athletic adolescents who engage in regular physical activity, and in football players three days after a tournament [7, 15] . In addition, five months of anaerobic training induced an elevation in the circulating PON1 activity [83] . Moreover, the PON1 activity was found to have increased following a single maximal exercise; and this effect was much more pronounced in active than in sedentary subjects [63, 64] . However, in men with metabolic syndrome, no effect of a single submaximal exercise on the circulating PON1 was demonstrated [81] . Similarly, no effect of an endurance exercise was noted in healthy Iranian men, probably due to their different genetic background from Caucasians [24] . From these demonstrations, it seems feasible that the PON1 gene polymorphism markedly affects the enzyme response to exercise [57] .
Thus, it could be tentatively speculated that, at least in healthy subjects, physical activity increases PON1 activity resulting in improved HDL-C functionality.
It has also been well documented that the MPO activity becomes elevated in response to intensive exercise both in humans and animals [11, 52, 53] . However, it should be stressed that the main source of the circulating MPO is its release from the neutrophils, whose count in the blood is stimulated in response to exercise [54, 56] . Therefore, it is feasible that the MPO activity after exercise is a sign of the neutrophil degranulation and is an exercise-induced inflammatory response [70] . On the contrary, Richter et al. [72] found that endurance training significantly reduced the circulating MPO activity in persons with a diagnosed risk of coronary events. Similarly, Youssef et al. [96] demonstrated that three months of aerobic activity markedly decreased the circulating MPO activity in overweight/ obese adolescent girls. Thus, it seems feasible that low-intensity exercise positively affects the HDL-C functionality, decreasing the MPO but increasing the PON1 activity. However, it should be stressed that more studies concerning the effects of physical activity on the HDL-C functionality are needed to confirm this hypothesis.
In conclusion, despite many years of experimental and clinical studies, we are still far from developing an adequate description of all the risk factors responsible for atherosclerosis and its serious health consequences, such as CVD. However, despite these doubts, the identification of dysfunctional HDL-cholesterol and the factors that contribute to its functionality have shed new light on the mechanisms involved in atherosclerosis. Additionally, according to Libby [43] , the thinking of most scientists about atherosclerosis is too simple because each potential cause of the disease is usually studied separately from the others, without taking into consideration their mutual associations.
